Abstract
Brill et al. [1] report on the potential utility of mycophenolate mofetil (MMF) as a steroid-sparing agent in chronic pulmonary sarcoidosis in 10 patients with some success in the reduction of systemic steroids while preserving lung function and clinical stability. Although this provides a welcome possible alternative to other steroid-sparing agents that might have more adverse events, such as methotrexate or azathioprine, MMF has been more recently associated [2,3] with the development of bronchiectasis (in addition to its well-known problems of gastrointestinal disturbance and leucopenia).